Morgan Stanley provides an update on CSL's Japanese rival Takeda. Takeda reported flat immunoglobulin growth in the second quarter. The company did not provide any specifics on plasma collection other than potential timing shift in plasma supply due to covid.

On the other hand, CSL's immunoglobulin sales grew by 14% int he second half. The broker assesses demand on CSL's safety stock to be robust with FY21 solid net profit guidance.

Equal-weight rating with a target price of $282. Industry view: In-line.

Sector: Pharmaceuticals, Biotechnology & Life Sciences.

Target price is $282.00.Current Price is $291.46. Difference: ($9.46) - (brackets indicate current price is over target). If CSL meets the Morgan Stanley target it will return approximately -3% (excluding dividends, fees and charges - negative figures indicate an expected loss).

© 2020 Acquisdata Pty Ltd., source FN Arena